Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Anti-inflammatory effects of the GAG-binding CXCL9(74-103) peptide in dinitrofluorobenzene-induced contact hypersensitivity in mice.

Vanheule V, Crijns H, Poosti F, Ruytinx P, Berghmans N, Gerlza T, Ronsse I, Pörtner N, Matthys P, Kungl AJ, Opdenakker G, Struyf S, Proost P.

Clin Exp Allergy. 2018 Oct;48(10):1333-1344. doi: 10.1111/cea.13227. Epub 2018 Aug 14.

PMID:
29978510
2.

Monocytes from patients with Primary Ciliary Dyskinesia show enhanced inflammatory properties and produce higher levels of pro-inflammatory cytokines.

Cockx M, Gouwy M, Ruytinx P, Lodewijckx I, Van Hout A, Knoops S, Pörtner N, Ronsse I, Vanbrabant L, Godding V, De Boeck K, Van Damme J, Boon M, Struyf S.

Sci Rep. 2017 Nov 7;7(1):14657. doi: 10.1038/s41598-017-15027-y.

3.

Relative distribution and biological characterization of CXCL4L1 isoforms in platelets from healthy donors.

Ruytinx P, Janssens R, Berghmans N, Gouwy M, Ronsse I, Liekens S, Proost P, Van Damme J, Struyf S.

Biochem Pharmacol. 2017 Dec 1;145:123-131. doi: 10.1016/j.bcp.2017.08.020. Epub 2017 Aug 30.

PMID:
28859966
4.

Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle.

Dinsart C, Pervolaraki K, Stroh-Dege A, Lavie M, Ronsse I, Rommelaere J, Van Damme J, Van Raemdonck K, Struyf S.

Hum Gene Ther. 2017 Mar;28(3):295-306. doi: 10.1089/hum.2016.108. Epub 2016 Dec 29.

PMID:
28042949
5.

The Positively Charged COOH-terminal Glycosaminoglycan-binding CXCL9(74-103) Peptide Inhibits CXCL8-induced Neutrophil Extravasation and Monosodium Urate Crystal-induced Gout in Mice.

Vanheule V, Janssens R, Boff D, Kitic N, Berghmans N, Ronsse I, Kungl AJ, Amaral FA, Teixeira MM, Van Damme J, Proost P, Mortier A.

J Biol Chem. 2015 Aug 28;290(35):21292-304. doi: 10.1074/jbc.M115.649855. Epub 2015 Jul 16.

6.

Intradermal air pouch leukocytosis as an in vivo test for nanoparticles.

Vandooren J, Berghmans N, Dillen C, Van Aelst I, Ronsse I, Israel LL, Rosenberger I, Kreuter J, Lellouche JP, Michaeli S, Locatelli E, Franchini MC, Aiertza MK, Sánchez-Abella L, Loinaz I, Edwards DR, Shenkman L, Opdenakker G.

Int J Nanomedicine. 2013;8:4745-56. doi: 10.2147/IJN.S51628. Epub 2013 Dec 13.

7.

Citrullination of TNF-α by peptidylarginine deiminases reduces its capacity to stimulate the production of inflammatory chemokines.

Moelants EA, Mortier A, Grauwen K, Ronsse I, Van Damme J, Proost P.

Cytokine. 2013 Jan;61(1):161-7. doi: 10.1016/j.cyto.2012.09.011. Epub 2012 Oct 15.

PMID:
23075670
8.

Biological activity of CXCL8 forms generated by alternative cleavage of the signal peptide or by aminopeptidase-mediated truncation.

Mortier A, Berghmans N, Ronsse I, Grauwen K, Stegen S, Van Damme J, Proost P.

PLoS One. 2011;6(8):e23913. doi: 10.1371/journal.pone.0023913. Epub 2011 Aug 31.

9.

Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine Deiminases (PAD) differently affects its biological activity.

Mortier A, Loos T, Gouwy M, Ronsse I, Van Damme J, Proost P.

J Biol Chem. 2010 Sep 24;285(39):29750-9. doi: 10.1074/jbc.M110.119388. Epub 2010 Jul 14.

10.

The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.

Vandercappellen J, Liekens S, Bronckaers A, Noppen S, Ronsse I, Dillen C, Belleri M, Mitola S, Proost P, Presta M, Struyf S, Van Damme J.

Mol Cancer Res. 2010 Mar;8(3):322-34. doi: 10.1158/1541-7786.MCR-09-0176. Epub 2010 Mar 9.

11.

Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation.

Proost P, Loos T, Mortier A, Schutyser E, Gouwy M, Noppen S, Dillen C, Ronsse I, Conings R, Struyf S, Opdenakker G, Maudgal PC, Van Damme J.

J Exp Med. 2008 Sep 1;205(9):2085-97. doi: 10.1084/jem.20080305. Epub 2008 Aug 18.

12.

Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation.

Loos T, Mortier A, Gouwy M, Ronsse I, Put W, Lenaerts JP, Van Damme J, Proost P.

Blood. 2008 Oct 1;112(7):2648-56. doi: 10.1182/blood-2008-04-149039. Epub 2008 Jul 21.

PMID:
18645041
13.

Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration.

Proost P, Mortier A, Loos T, Vandercappellen J, Gouwy M, Ronsse I, Schutyser E, Put W, Parmentier M, Struyf S, Van Damme J.

Blood. 2007 Jul 1;110(1):37-44. Epub 2007 Mar 15.

PMID:
17363734
14.

TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis.

Loos T, Dekeyzer L, Struyf S, Schutyser E, Gijsbers K, Gouwy M, Fraeyman A, Put W, Ronsse I, Grillet B, Opdenakker G, Van Damme J, Proost P.

Lab Invest. 2006 Sep;86(9):902-16. Epub 2006 Jul 17.

15.

Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies.

Proost P, Struyf S, Loos T, Gouwy M, Schutyser E, Conings R, Ronsse I, Parmentier M, Grillet B, Opdenakker G, Balzarini J, Van Damme J.

Arthritis Res Ther. 2006;8(4):R107.

16.

Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids.

Proost P, Verpoest S, Van de Borne K, Schutyser E, Struyf S, Put W, Ronsse I, Grillet B, Opdenakker G, Van Damme J.

J Leukoc Biol. 2004 May;75(5):777-84. Epub 2004 Mar 2.

PMID:
14996826
17.

Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy.

Nelissen I, Martens E, Van den Steen PE, Proost P, Ronsse I, Opdenakker G.

Brain. 2003 Jun;126(Pt 6):1371-81.

PMID:
12764058
18.

Gelatinase B, PECAM-1 and MCP-3 gene polymorphisms in Belgian multiple sclerosis.

Nelissen I, Dubois B, Goris A, Ronsse I, Carton H, Opdenakker G.

J Neurol Sci. 2002 Aug 15;200(1-2):43-8.

PMID:
12127674
19.

Regulation of gelatinase B in human monocytic and endothelial cells by PECAM-1 ligation and its modulation by interferon-beta.

Nelissen I, Ronsse I, Van Damme J, Opdenakker G.

J Leukoc Biol. 2002 Jan;71(1):89-98.

PMID:
11781384
20.

Lack of association between the interferon regulatory factor-1 (IRF1) locus at 5q31.1 and multiple sclerosis in Germany, northern Italy, Sardinia and Sweden.

Vandenbroeck K, Hardt C, Louage J, Fiten P, Jäckel S, Ronsse I, Epplen JT, Grimaldi LM, Olsson T, Marrosu MG, Billiau A, Opdenakker G.

Genes Immun. 2000;1(4):290-2.

21.

High-resolution analysis of IL-6 minisatellite polymorphism in Sardinian multiple sclerosis: effect on course and onset of disease.

Vandenbroeck K, Fiten P, Ronsse I, Goris A, Porru I, Melis C, Rolesu M, Billiau A, Marrosu MG, Opdenakker G.

Genes Immun. 2000 Oct;1(7):460-3.

22.

Analysis of an IFN-gamma gene (IFNG) polymorphism in multiple sclerosis in Europe: effect of population structure on association with disease.

Goris A, Epplen C, Fiten P, Andersson M, Murru R, Sciacca FL, Ronsse I, Jäckel S, Epplen JT, Marrosu MG, Olsson T, Grimaldi LM, Opdenakker G, Billiau A, Vandenbroeck K.

J Interferon Cytokine Res. 1999 Sep;19(9):1037-46.

PMID:
10505747
24.

Effect of VH and VL consensus sequence-specific primers on the binding and neutralizing potential of a single-chain FV directed towards HuIFN-gamma.

Froyen G, Hendrix D, Ronsse I, Fiten P, Martens E, Billiau A.

Mol Immunol. 1995 May;32(7):515-21.

PMID:
7783754
25.

Supplemental Content

Loading ...
Support Center